IL17A and infection: A meta-analysis of randomized and extension trials estimated overall infection exposure-adjusted incidence rates (EAIRs) of ~57.8 and serious infections of ~1.1 per 100 patient-years with IL-17 inhibitors, with Candida notably more common but serious infections still rare [10].